Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.

Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

Abstract: The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and/or at least one lipid and/or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.

Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises Vitamin B12. The solution furthermore comprises butaphosphan to stabilize the Vitamin B12 and the inclusion of butaphosphan may have synergistic activity with the minerals.

Abstract: Synthesizing a drug-organic-acid-anhydride conjugate using docetaxel as a drug, including: mixing aconitic anhydride with a chlorinating reagent to produce a first mixture; dissolving the first mixture in an organic solvent to produce a dissolved mixture; stirring the dissolved mixture; evaporating the organic solvent from the dissolved mixture to produce a second mixture; washing the second mixture with an impurity remover to remove impurities and to produce an aconitic anhydride chloride solution; and mixing the docetaxel with the aconitic anhydride chloride solution to produce the drug-organic-acid-anhydride conjugate.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract: Provided herein are materials and methods that include utilizing atom transfer radical polymerization (ATRP) initiator molecules that maintain a positive charge during biomacro-initiator synthesis.

Abstract: The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.

Abstract: The present invention relates to biomarkers of use for treating Trop-2 expressing cancer with an anti-Trop-2 ADC comprising an anti-Trop-2 antibody conjugated to an inhibitor of topoisomerase I, preferably SN-38 or DxD. The anti-Trop-2 ADC may be administered as a monotherapy or as a combination therapy with one or more anti-cancer agents, such as DDR inhibitors. Therapy with the ADC alone or in combination with other anti-cancer agents can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Abstract: The present invention concerns methods of diagnosing and treating a malignant neoplasm of the CNS by detecting mammalian tissue expressing integrin alpha 10 subunit or a fragment or variant thereof, and administering a drug specific for integrin alpha 10 subunit.

Abstract: A compound of formula (I) wherein RL is a linker for connection to a cell binding agent.

Abstract: Described herein are compositions that include an assembly of self-assembling conjugates. The self-assembling conjugates may include a polypeptide having a transition temperature (17) above 50° C. when the polypeptide is not attached to the conjugate, an albumin binding domain (ABD) attached to a first end of the polypeptide, and at least one molecule attached to a second end of the polypeptide through a cysteine group, wherein the molecule has an octanol-water distribution coefficient (log D) of greater than or equal to 1.5 at a pH of 7.4 when the molecule is not attached to the conjugate. Also described herein are methods of using the compositions.

Abstract: The invention provides a composition which is suitable for the delivery of RNA, which composition comprises (i) particles contained in a liquid phase, wherein the particles comprise RNA and a lipid composition, and (ii) a salt composition. The lipid composition comprises (i-a) a cholesterol derivative, (i-b) a phosphoglyceride, and (i-c) a pegylated phosphoglyceride. Further provided is a method for preparing the composition.

Abstract: The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

Abstract: A conjugate comprising (a) a nanodiamond; (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.

Abstract: A nanocomposition for use in treating cardiac, oncologic, bariatric, or dermatologic indications, conditions and diseases condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a RGD, or iRGD targeting agent. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to the target tissue, and found in only target tissue; and administering light to activate the IR700, thereby producing an ROS.

Abstract: This invention relates to polynucleotides comprising optimized CLN7 open reading frame (ORF) sequences, viral vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of CLN7, such as variant late infantile neuronal ceroid lipofuscinoses (vLINCL; CLN7 disease).

Abstract: The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a Wiskott-Aldrich Syndrome protein. In some embodiments, the expression vector is a self-inactivating lentiviral vector. In some embodiments, the Wiskott-Aldrich Syndrome protein is used to alleviate the pathologies associated with Wiskott-Aldrich Syndrome.

Abstract: The present disclosure provides bidirectional nucleic acid constructs that allow enhanced insertion and expression of a nucleic acid sequence of interest, e.g., encoding a therapeutic agent such as a polypeptide.

Abstract: The disclosure relates to compositions and methods for promoting cardiomyocyte cytokinesis and cardiomyocyte proliferation and for use in cardiac regenerative therapy. Embodiments of the disclosure are particularly useful for promoting cytokinesis in adult cardiomyocytes. In embodiments, the disclosure relates to the expression of human cyclin A2 (CCNA2) under the control of a cardiac Troponin T (cTNT) promoter to promote cytokinesis of adult human cardiomyocytes.

Abstract: An expression cassette for gene silencing and replacement, including, in operable communication, a promoter, an expression attenuator, a nucleotide sequence encoding a gene for a replacement target protein, and an shRNA sequence for knockdown of an endogenous variant of the target protein, wherein the promoter, the expression attenuator, the nucleotide sequence encoding the gene for the replacement target protein, and the shRNA are expressed as a single transcript. Also included are expression vectors and cells. Also included are methods of silencing and replacement of a target gene in a cell in culture by transforming the cells with the expression vectors described herein. Also included are minimal expression cassettes suitable for therapeutic methods.

Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radio-nuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.

Abstract: The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.

Abstract: The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the synthesis method comprises the following steps in the following order: a. providing a radionuclide precursor solution into a first vial, b. transferring the radionuclide precursor solution into a reactor, c. providing a reaction buffer solution into said first vial containing residual radionuclide precursor solution, d. transferring the buffer reaction solution and residual radionuclide precursor solution from said first vial into the reactor, e. transferring a peptide solution comprising the somatostatin receptor binding peptide linked to a chelating agent, into the reactor, f. reacting the somatostatin receptor binding peptide linked to a chelating agent with said radionuclide in the reactor to obtain the radionuclide complex, g. recovering said radionuclide complex.

Abstract: A mobile system for disinfecting a surface is described, having a chamber having an inner housing at least partially surrounding the surface, a disinfectant source at the inner housing to apply a disinfectant to at least one portion of the surface, and a motor for moving the chamber along a predetermined path from a first position to a second position, the at least one portion of the surface contacted by disinfectant changing as a result of the chamber moving from the first position to the second position.

Abstract: A footwear sanitizing system; the footwear sanitizing system includes a sterilizing unit, a first shoe tree, a second shoe tree, and a charger working in combination to provide a sterilizing device for footwear. The footwear sanitizing system provides internal and external sanitization of footwear worn in healthcare facilities through ultraviolet radiation, preventing unwanted transfer of bacteria and germs both within and outside of the environment of use of the footwear. Users are notified of completion of the sanitization via a software application program hosted on a computing device. The footwear sanitizing system reduces the risks of nosocomial infections and healthcare-associated infections occurring within, and transferred from, healthcare facilities via a necessary fomite.

Abstract: An ultraviolet light germicidal irradiation device includes a base member having a mounting plate for detachably securing the base member to a selected surface; an extension member detachably and substantially vertically secured to the base member; an arm member rotationally secured to the extension member, whereby, a top portion of the arm member is disposed outside the periphery of either side of an object to be decontaminated; an ultraviolet light housing pivotally secured to the top portion of the arm member, whereby, a front portion of the ultraviolet light housing has a pivoting range from at least twenty degrees above a horizontal plane to forty degrees below the horizontal plane; and an ultraviolet light lamp disposed inside the ultraviolet light housing, the ultraviolet light lamp emitting an ultraviolet light at a preselected wave length that destroys a preselected virus without injuring humans.

Abstract: A dual-purpose sterilization box includes an outer box set provided with sterilization light source elements, an inner box placed in a housing space inside the outer box set and provided with through holes on side walls thereof corresponding to the sterilization light source elements so that the sterilization light source elements can emit sterilization light into the housing space around 360 degrees to sterilize items placed in the housing space. A light guide box for storing food can be placed in the housing space, so that sterilization light source elements in the outer box set can emit sterilization light to an optical structure of light incident portion of the light guide box and a light emitting surface of the light guide box can project the incident sterilization light into the sterilization space in the light guide box through 360 degrees to sterilize the storage food.

Abstract: A footwear sanitation station with UVC emitters to radiate footwear positioned on supporting grates through which UVC radiation can irradiate outsoles of the footwear. The station includes one or more different types of sensors, a power indicator, a sanitize indicator, a power source, and a a controller with a processor allowing the station to operate in different modes, including a Stand-By Mode and a Sanitize Mode, and to activate the power indicator and the sanitize indicator to provide cues to a user of the Mode of operation.

Abstract: A germicidal system for use in disinfecting one or more contact surfaces includes one or more germicidal devices each comprising a germicidal light source. The one or more germicidal devices may be connected to a network, which allows for controlling the operational parameters of the one or more germicidal devices and/or collecting information from the one or more germicidal devices.

Abstract: A door handle assembly for a vehicular door of a vehicle includes a base portion disposed at the vehicular door, a handle portion, and an ultraviolet (UV) radiation emitter. The handle portion includes a grasping portion configured for a user to grasp when operating the door handle assembly. The handle portion is movable relative to the base portion by a user grasping the grasping portion to actuate a latch mechanism for opening the vehicular door. The UV radiation emitter, when electrically powered, irradiates at least the grasping portion of the handle portion with UV radiation.

Abstract: An apparatus and method for securely and safely storing an item includes a container having a plurality of walls configured to define an interior space of the container and an entry panel positioned in at least a portion of one of the plurality of walls and operable to open and reveal the interior space of the container. An open/close controller is coupled to the entry panel and configured to control the opening and closing of the entry panel. A germicidal controller is positioned within the interior space of the container and configured to provide a germicide to the interior space. The container also includes circuitry coupled to the open/close controller and germicidal controller and a memory coupled to the circuitry having a plurality of instructions executed by the circuitry.

Abstract: A piggybacking apparatus for mobile devices is provided. The piggybacking apparatus may be dimensioned and adapted to removably attach to the surface area of a mobile electronic device, such as a smart phone, in a generally coextensive manner. The piggybacking apparatus may provide a pouch for retrievably storing fluid and semifluid product that a user wants handy when they are handling the mobile electronic device, Through a conduit the user may urge the product from the pouch when and where desired. The piggybacking apparatus may also provide attachment points along a periphery thereof for operatively associating with the mobile electronic device in the coextensive manner, or alternatively to a case of the mobile electronic device, or even in between the two.

Abstract: A method and device for treating contaminated or potentially contaminated items is provided. The method will include the steps of placing the items in a reactor. The reactor is then sealed and ozone or ozonated gas is sent into the reactor. The items are held in the reactor long enough to complete the decontamination process. The reactor is then opened. Next there is a period of passive reaction so that the ozone can be degraded from the pores and surfaces of the items. The device provided herein includes a reactor, an ozone generator, a rack for holding said items; and a monitor for determining the level of ozone in the reactor.

Abstract: The present disclosure provides a cover or sleeve for use with a sterilization container comprising a collapsible enclosure configured to conform to the shape and size of the sterilization container. The collapsible enclosure includes an inner layer configured to withstand a sterilization procedure and a protective layer bonded to the inner layer. The protective layer is configured to protect the inner layer and to withstand the sterilization procedure. The enclosure further comprises a scalable opening for receiving the sterilization container within the interior of the enclosure. The collapsible enclosure is universally adapted for use for a variety of validated sterilization methods, such as steam, hydrogen peroxide, gas plasma, ozone, ethylene oxide and the like and with various sterilization trays, baskets and the like.

Abstract: An air disinfection device includes: a housing including an inlet port and a disinfection chamber that has a shape of a frustum; and a disinfection head disposed in the inlet port and including a fan for taking air into the housing, a filter for filtering the air; and a light source for generating disinfection light that forms a light frustum and disinfects the air in the disinfection chamber. The air disinfection device further includes a power source that provides electrical power for the disinfection head. The light source is arranged so that the light frustum is coaxial with the chamber frustum, and the light and chamber frusta diverge along the same direction. The lateral surface of the light frustum can coincide with the inner lateral surface of the disinfection chamber and the entire portion of a space defined by the disinfection chamber is located within the light frustum.

Abstract: This invention relates to an air purification apparatuses and methods for air purification. The air purification apparatuses pass air through energy beams that form one or more fields of energy within a chamber to produce an outflow of sterilized air. In some aspects, a charge generation system is implemented to repel particles from the chamber walls. In some aspects, the fields of energy extend across substantially an entirety of the cross sectional area of the interior volume of the chamber and longitudinally within the chamber. In some aspects, a controller is configured to rotate a beam of collimated light energy within the chamber at a rotational velocity corresponding to at least V/W, wherein V is the linear velocity of a particle within the chamber along the longitudinal axis, and W is the width of the beam of collimated light energy.

Abstract: A treatment apparatus and method of treating an inside volume of a mobile vehicle using the apparatus. The method includes the steps of: a) placing a treatment unit in an operative position with respect to the mobile vehicle, the treatment unit having: i) a frame; ii) a source of UV light; and iii) an air mover for controllably directing air within the inside volume to be exposed to UV rays generated by the UV light source; and b) operating the treatment unit and thereby causing air within the inside volume to be disinfected by UV light rays from the UV light source and circulated within the inside volume.

Abstract: Devices and methods for sterilizing an enclosed space using ozone are disclosed herein. Various embodiments of the devices and methods also provide for accelerated degradation of the ozone upon sterilization. In some embodiments, a disclosed sterilization unit includes a first housing defining an ozone generation cavity, an ozone generator disposed within the ozone generation cavity, a second housing defining an ozone degradation cavity, and an ozone degrader disposed within the ozone degradation cavity. The sterilization unit of various embodiments is configured to cycle air between the enclosed space and the ozone generation cavity during an ozone generation cycle to sterilize the enclosed space; similarly, the unit is further configured to cycle air between the enclosed space and the ozone degradation cavity during an ozone degradation cycle to return the air within the enclosed space to safe ozone levels.

Abstract: There is disclosed a formulation suitable for the reduction or prevention of contamination of articles by microorganisms. The formulation includes at least one block copolymer of ethylene oxide and propylene oxide, at least one polyacrylic acid salt, and at least one propoxylated ethylenediamine compound.

Abstract: A method for applying a polymeric composition discharged in a fluid form from a slot die applicator to a substrate, the slot die applicator including a slot opening, a first lip, and a second lip, the slot opening located between the first lip and the second lip; and the substrate having a first surface disposed opposite of a second surface and an unconstrained caliper, Hs, the method comprising the steps of positioning the substrate carrier adjacent the slot die applicator to define a minimum distance, Hg, between the substrate carrier and the first lip and the second lip that is substantially the same or less than the unconstrained caliper, Hs, of the substrate. The polymeric composition has Tensile Strength at Yield of from about 0.5 MPa to about 10 MPa, as measured according to the Tensile Strength Test Method described herein.

Abstract: An ostomy device has a switchable adhesive layer located between a backing layer and an absorbent adhesive layer. The switchable adhesive layer has a photoinitiator reactive to visible light and the absorbent adhesive layer is a skin-facing layer having absorbent particles.

Abstract: In various embodiments, the present invention is directed to a drug-loaded amino acid based poly(ester urea) pouch or pocket sized to receive implanted devices that produces localized drug delivery. In some embodiments, the present invention is directed to an antibiotic-loaded L-Valine poly(ester urea) pouch or pocket that provides localized antibiotic delivery for CIEDs or other implanted devices. In one or more embodiments, the amount and rate of antibiotic release are dependent upon the thickness and loading concentration of the film. This dependence of release on thickness and loading concentration gives a handle to fabricate PEU-A pouches or pockets with any desired release profile that can locally deliver the therapeutically relevant amount of antibiotic.

Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.

Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.

Abstract: A joint spacer is provided for treatment of a joint of a human subject, the joint spacer including a pouch having a wall including a dermal graft material. The joint spacer is configured to be inserted into a space of the joint, and is shaped, when the pouch is inserted into the space and filled, to provide mechanical support to the joint. Other embodiments are also described.

Abstract: Biomaterial compositions for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include a plurality of particulate structures. The biomaterial compositions include poly(glycerol sebacate) (PGS) and an antifibrotic. The biomaterial compositions can also include poly(glycerol sebacate) acrylate (PGSA) and an antifibrotic. The biomaterial compositions can further include acellular extracellular matrix (ECM) derived from a mammalian tissue source, such as small intestine submucosa, cardiac tissue and placental tissue. The biomaterial compositions are adapted to modulate inflammation of damaged tissue and induce neovascularization, host cell proliferation, remodeling of damaged tissue, and regeneration of new tissue and tissue structures.

Abstract: An object of the present invention is to provide a cell transplantation kit capable of exhibiting a high medical treatment effect by transplanted cells, a method for producing a sac-shaped structure that is used in the cell transplantation kit, and a therapeutic agent for diabetes containing the cell transplantation kit. According to the present invention, there is provided a cell transplantation kit including a first sac-shaped structure consisting of a membrane having pores of an average pore diameter of 0.2 mm or less, and a plurality of second sac-shaped structures having an average long diameter larger than the average pore diameter of the pores of the first sac-shaped structure, in which at least a part of the plurality of second sac-shaped structures contain cells. According to the present invention, there is provided a method for producing a sac-shaped structure that is used in the cell transplantation kit.